MRI-1867

a cannabinoid-1 receptor (CB1R) and inducible NO synthase (iNOS) inhibitor

Also Known As:

(4S)-N-(1-aminoethylidene)-5-(4-chlorophenyl)-N'-(4-chlorophenyl)sulfonyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide

Networked: 4 relevant articles (1 outcomes, 0 trials/studies)

1.	Fibrosis (Cirrhosis) 01/01/2021 - "Here, we evaluated the therapeutic efficacy of MRI-1867 in bleomycin-induced skin fibrosis. " 01/01/2021 - "Peripheral Hybrid CB1R and iNOS Antagonist MRI-1867 Displays Anti-Fibrotic Efficacy in Bleomycin-Induced Skin Fibrosis." 01/01/2021 - "MRI-1867 treatment attenuated bleomycin-induced established skin fibrosis and the associated increase in endocannabinoids in Mdr1a/b-Bcrp KO mice but not in B6 mice. "
2.	Mitochondrial Diseases (Mitochondrial Disease) 01/01/2021 - "Moreover, MRI-1867 treatment abrogated bleomycin-induced increases in lung levels of the profibrotic interleukin-11 via iNOS inhibition and reversed mitochondrial dysfunction via CB1 R inhibition. "
3.	Endotoxemia 08/22/2021 - "We conclude that (i) activation of peripheral CB1R plays a dominant role in promoting alcohol intake and (ii) the iNOS inhibitory function of MRI-1867 helps in mitigating the alcohol-induced increase in endotoxemia."
4.	Obesity 01/01/2020 - "Here, we describe the effect of a novel peripherally restricted, orally bioavailable dual CB1 receptor/iNOS antagonist, MRI-1867 (3 mg·kg-1 ), in ameliorating obesity-induced CKD, and compared its metabolic and renal efficacies to a stand-alone peripheral CB1 receptor antagonist (JD5037; 3 mg·kg-1 ), iNOS antagonist (1400W; 10 mg·kg-1 ), and pair feeding. "

1.	indium-bleomycin
2.	Bleomycin (Blenoxane)
3.	Endocannabinoids
4.	CB1 Cannabinoid Receptor (CB1 Receptor)
5.	Interleukin-11 (Interleukin 11)
6.	JD5037